Pharmacokinetics, Tolerability and Safety of NEX-18a

Sponsor

Nanexa AB (Industry)

Overall Status

Terminated

CT.gov ID

NCT05048498

Collaborator

Uppsala University (Other)

Enrollment

Locations

Arms

9.5

Actual Duration (Months)

Patient Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study will evaluate the safety, tolerability and pharmacokinetics of NEX-18a, a long-acting injectable azacitidine, in patients diagnosed with intermediate 2 or higher-risk MDS, CMML, or AML and already on treatment with azacitidine.

Condition or Disease	Intervention/Treatment	Phase
Myelodysplastic Syndromes (MDS) Chronic Myelomonocytic Leukemia (CMML) Acute Myeloid Leukemia (AML)	Drug: NEX-18a injection Drug: Azacitidine Injection	Phase 1

Detailed Description

Since 2010, subcutaneous treatment with azacitidine has been the first-line treatment for patients with high-risk MDS. Azacitidine has been established as a standard of care and is described in the National Comprehensive Cancer Network (NCCN) guidelines as a core component of optimal treatment of MDS. However, mainly due to its short half-life (41 minutes) when administered subcutaneously azacitidine should, according to the approved label, be administered for seven consecutive days at a dose of 75 mg/m2 body surface area (BSA) each 28-day cycle. In the Nordic Guidelines, two alternative dosing schedules may also be considered: 100 mg/m2 BSA sc day 1-5 or 75 mg/m2 BSA sc day 1-5 + 8-9 (to avoid injection during weekends).

Nanexa AB has developed NEX-18a, a subcutaneous injection of azacitidine with extended-release based on the drug delivery system, PharmaShell®. Drug particles are enclosed in a coating with controlled solubility, and as the coating dissolves over time the drug is released in a predefined manner. This technique provides a way to create drugs with a prolonged release for parenteral administration. The technology used by Nanexa to manufacture the coating is via Atomic Layer Deposition (ALD). In ALD, reactive gases are used which build up a surface coating with high precision, atomic layer by atomic layer.

NEX-18a will offer a benefit to current azacitidine treatment with a reduction of subcutaneous administrations, decreased need for pre-medication, and will reduce the time each patient has to spend in the hospital in order to receive the treatment in each cycle. In addition, the patients will spend less time traveling to and from the hospital and from a health care perspective, one injection instead of seven per cycle will reduce the time and the resources the health care provider dedicates to treating the patients.

Study Design

Study Type:

Interventional

Actual Enrollment :

2 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML

Actual Study Start Date :

Apr 27, 2021

Actual Primary Completion Date :

Feb 10, 2022

Actual Study Completion Date :

Feb 10, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Azacitidine Treatment phase 1: the patients will receive regular treatment with azacitidine for 4 days. Treatment phase 2: the patients will receive regular treatment with azacitidine for 3 days.	Drug: Azacitidine Injection In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days. Other Names: Azacitidine 5-azacitidine Vidaza
Experimental: NEX-18a Treatment phase 1: the azacitidine dose for day 5 will be replaced by a single dose NEX-18a Treatment phase 2: the azacitidine dose for day 4 and 5 will be replaced by a single dose NEX-18a	Drug: NEX-18a injection In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection. In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection. Other Names: PharmaShell Azacitidine 5-azacitidine

Arm

Intervention/Treatment

Active Comparator: Azacitidine

Treatment phase 1: the patients will receive regular treatment with azacitidine for 4 days. Treatment phase 2: the patients will receive regular treatment with azacitidine for 3 days.

Drug: Azacitidine Injection

In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.

Other Names:

Azacitidine

5-azacitidine

Vidaza

Experimental: NEX-18a

Treatment phase 1: the azacitidine dose for day 5 will be replaced by a single dose NEX-18a Treatment phase 2: the azacitidine dose for day 4 and 5 will be replaced by a single dose NEX-18a

Drug: NEX-18a injection

In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection. In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection.

Other Names:

PharmaShell

Azacitidine

5-azacitidine

Outcome Measures

Primary Outcome Measures

Hematology and Clinical Chemistry analyses [0-30 days]
Change from baseline to 30 days follow-up. Descriptive individual data.
Adverse events [0-30 days]
Change from baseline to 30 days follow-up. Descriptive individual data.
Vital signs [0-30 days]
Change from baseline to 30 days follow-up. Descriptive individual data.
Physical examination [0-30 days]
Change from baseline to 30 days follow-up. Descriptive individual data.
Local tolerance (injection site) [0-30 days]
Change from baseline to 30 days follow-up. Descriptive individual data.
Concomitant medications/therapy [0-30 days]
Change from baseline to 30 days follow-up. Descriptive individual data.

Secondary Outcome Measures

AUC-time curve [0-24 h]
From time 0 to 24 hours
AUC from time 0-last [0-336 h]
From time 0 to last
AUC from time 0 to infinity [0-336 h]
From time 0 to infinity
Plasma Concentration [0-336 h]
Maximum Plasma Concentration
Plasma Concentration over time [0-336 h]
Plasma Concentration at 336h
Half-life measurement [0-336 h]
Terminal elimination half-life
Measurement of distribution [0-336 h]
Volume of distribution
Elimination [0-336 h]
Clearance
Local tolerance of NEX-18a [0-30 days]
Change from baseline to 30 days follow-up. Descriptive individual data. The local tolerance will be measured by inspection of injection sites. Pain, tenderness erythema/redness, and induration/swelling will be assessed by a four-grade scale where 1 is mild and 4 is potentially life threatening.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of written informed consent prior to any study specific procedures.
Female and male patients ≥ 18 years of age.
Body Mass Index (BMI) > 19 and < 30 kg/m2 BSA at screening.
Treatment with azacitidine corresponding to 100 mg/m2 BSA x 5 per treatment cycle for at least six cycles for:
intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS)
chronic myelomonocytic leukemia (CMML) with 10-29 % marrow blasts
acute myeloid leukemia (AML) according to World Health Organization (WHO) classification
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Recovery of Hematology and Clin. Chemistry assessment according to clinical praxis at the start of the last azacitidine treatment cycle before the screening visit.
Female subject must be of non-childbearing potential (defined as pre-menopausal females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as 12 months' amenorrhoea [in questionable cases a blood sample with simultaneous follicle stimulation hormone 25-140 IE/L and estradiol < 200 pmol/L is confirmatory])
Male patients must agree to use an adequate method of contraception. Male patients who are sexually active must use, with their partner, a condom AND one of the following methods of highly effective contraception from the time of IMP administration until 90 days after the last dose of IMP.
oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable or implanted hormonal contraceptives
intrauterine device
intrauterine system (for example progestin-releasing coil)
vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate)
bilateral tubal occlusion or hysterectomy
Willingness and ability to comply with study procedures, visit schedules, study restrictions, and requirements.

Exclusion Criteria:

The patient has participated in any other investigational/interventional trial including an investigational drug within 30 days (or five half-lives of the study drug prior to screening, whichever is longer) prior to screening.
Diagnosis of malignant disease within the previous 5 years (excluding basal cell carcinoma of the skin without complications, "in-situ" carcinoma of the cervix or breast, or other local malignancy excised or irradiated with a high probability of cure).
Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.
The patient has a history of alcohol abuse or drug abuse within the past 12 months.
Any condition including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study.
Lack of suitability for participation in the study, for any reason, judged by the Investigator.